When do the patents on MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN expire, and when will MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN go generic?

Sponsor	Phase
Suez Canal University	N/A
Cairo University	N/A
University of Sao Paulo	N/A

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Belmora Llc	MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN	levonordefrin; mepivacaine hydrochloride	INJECTABLE;INJECTION	084850-002	Oct 21, 1983		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 29, 2026

Mepivacaine hydrochloride with levonordefrin is a mature dental local anesthetic combination with limited patent protection, low switching costs and modest product-level revenue visibility. Its commercial performance is driven primarily by dental procedure volumes, distributor availability, contract pricing and manufacturing reliability rather than by innovation or exclusivity. Generic entry is already established, and the product has no meaningful biosimilar risk because it is a small-molecule injectable drug.

What is mepivacaine hydrochloride with levonordefrin?

Mepivacaine hydrochloride with levonordefrin is a local anesthetic used for infiltration and nerve-block anesthesia in dentistry. The common U.S. dental formulation contains:

Product attribute	Typical specification
Active anesthetic	Mepivacaine hydrochloride
Vasoconstrictor	Levonordefrin
Common concentration	2% mepivacaine hydrochloride
Levonordefrin concentration	1:20,000
Typical dental cartridge volume	1.8 mL
Route	Local infiltration or nerve block
Primary setting	Dental offices and oral surgery
Drug class	Amide local anesthetic with sympathomimetic vasoconstrictor

Levonordefrin reduces local blood flow and can prolong anesthetic effect while slowing systemic absorption. The combination is an older alternative to mepivacaine without a vasoconstrictor or to formulations containing epinephrine. U.S. labeling identifies dental infiltration and block anesthesia as the principal use cases. The labeling also includes cardiovascular, hypertensive and drug-interaction warnings associated with the vasoconstrictor component (U.S. Food and Drug Administration [FDA], n.d.-a).

The product is commonly associated with the historical Carbocaine brand and with generic dental cartridges. Product availability varies by manufacturer, distributor and national market.

What is the FDA regulatory status of mepivacaine with levonordefrin?

The product is an FDA-approved prescription local anesthetic when marketed under an approved new drug application or an abbreviated new drug application. It is supplied as a sterile injectable solution, generally in single-use dental cartridges.

The regulatory profile is mature:

The drug is not a biologic.
It does not require a biosimilar pathway.
It is eligible for generic competition under the abbreviated new drug application pathway.
Its clinical use is well established.
The principal regulatory risks concern manufacturing quality, sterility, supply continuity, labeling and cartridge performance.
There is no obvious regulatory exclusivity mechanism comparable to orphan-drug, pediatric or new chemical entity exclusivity.

The FDA-approved labeling emphasizes contraindications and precautions involving hypersensitivity to amide local anesthetics, cardiovascular disease, hypertension, thyroid disease, diabetes, sulfite sensitivity and interaction with monoamine oxidase inhibitors or tricyclic antidepressants, depending on the specific product label (FDA, n.d.-a).

What patents protect mepivacaine hydrochloride with levonordefrin?

The core active ingredients are old, off-patent small molecules. No commercially significant composition-of-matter patent is expected to block generic manufacture of mepivacaine hydrochloride with levonordefrin.

Protection category	Commercial assessment
Mepivacaine composition patent	Expired or commercially irrelevant
Levonordefrin composition patent	Expired or commercially irrelevant
Combination patent	No meaningful current barrier identified
Dental cartridge formulation patent	Low barrier; generally mature technology
Method-of-use patent	No material exclusivity expected for routine dental anesthesia
Manufacturing patent	Possible process know-how, but unlikely to prevent generic supply
Orange Book patent protection	No material active patent barrier expected

The relevant intellectual-property value is therefore concentrated in manufacturing processes, quality systems, product registrations, customer contracts, trademarks and distribution relationships. Those assets can delay or complicate entry for a new supplier, but they do not create durable exclusivity.

A current Orange Book review is the controlling source for any listed patent or exclusivity determination. The FDA Orange Book records approved products, reference-listed drugs, generic equivalents and certain patent information, but mature generic dental anesthetics generally have little or no active patent protection in the database (FDA, n.d.-b).

When does mepivacaine with levonordefrin lose exclusivity?

The product has effectively lost market exclusivity. Any original pioneer exclusivity and core patent rights expired long ago because mepivacaine and levonordefrin have been used clinically for decades.

The commercial consequence is immediate generic substitution, subject to state pharmacy rules, dental purchasing practices and the availability of therapeutically equivalent products. Market entry does not depend on waiting for a future patent expiration date.

Exclusivity timeline

Event	Timing assessment
Original development and approval	Historical; product dates to the mature local-anesthetic market
New chemical entity exclusivity	Expired
Original composition patents	Expired
Formulation exclusivity	No material current protection expected
Generic entry	Established
Current exclusivity	None of commercial significance

How many patents cover mepivacaine hydrochloride with levonordefrin?

No meaningful active patent estate is expected to cover the marketed combination in the United States. Patent counts can differ depending on whether expired patents, foreign family members, process patents and abandoned applications are included. A raw patent count would therefore overstate the product’s current protection.

The practical conclusion is more important than the count: a competitor with FDA-compliant manufacturing, a validated sterile filling process and sufficient distribution could compete without negotiating a patent license from the incumbent brand owner.

What are the formulation and manufacturing barriers?

The formulation itself is technically mature, but sterile injectable manufacturing creates a meaningful operational barrier.

Formulation characteristics

The product is generally a sterile aqueous solution in a dental cartridge. Critical quality attributes include:

Correct mepivacaine and levonordefrin concentrations
Sterility and endotoxin control
pH and osmolality
Container-closure integrity
Cartridge break resistance
Extractables and leachables
Dose uniformity
Stability under labeled storage conditions

Dental cartridges require specialized filling and packaging equipment. A supplier must also demonstrate compatibility between the solution, cartridge, stopper, aluminum seal and dental delivery system.

These requirements are not patent barriers. They are regulatory and operational barriers. A manufacturer can lose market share because of a warning letter, sterile-production deviation, component shortage or recall even when its legal rights are strong.

Manufacturing concentration

The commercial supply base is narrower than the number of theoretical generic suppliers. Dental anesthetic cartridges require specialized facilities, and many pharmaceutical manufacturers prioritize higher-value injectables over low-priced dental products. This can create temporary shortages and gives established suppliers leverage with dental distributors.

The strongest competitive advantages are:

Reliable cartridge production.
FDA-compliant sterile operations.
Broad dental-distributor access.
Low manufacturing cost.
Capacity to absorb supply interruptions.
Established purchasing contracts with dental service organizations.

Which companies compete with mepivacaine with levonordefrin?

Competition comes from both direct generic equivalents and clinically substitutable dental anesthetics.

Direct competitors

Direct competition includes branded and generic versions of 2% mepivacaine with levonordefrin, where available. Product ownership and availability can change through divestitures, contract manufacturing arrangements and supplier withdrawals.

Therapeutic alternatives

Alternative	Primary distinction
Plain mepivacaine	Avoids vasoconstrictor exposure; shorter or less prolonged effect in some uses
Lidocaine with epinephrine	Broadly used, often lower cost and widely stocked
Articaine with epinephrine	Strong position in dental infiltration anesthesia
Prilocaine formulations	Used in selected dental markets; local availability varies
Bupivacaine	Longer duration; less common for routine dental procedures
Local anesthetics with other vasoconstrictors	Used according to regional practice and labeling

The principal competitive threat is not a patented replacement. It is substitution by lidocaine with epinephrine, articaine with epinephrine or plain mepivacaine. Dental practitioners often select products based on habit, clinical preference, formulary status, patient cardiovascular considerations and availability.

What is the Orange Book status of the product?

The Orange Book is relevant for determining reference-listed drug status, generic equivalence and any listed patent or exclusivity information. For this mature product category, the expected commercial profile is:

Reference product status may be associated with a historical branded application.
Generic equivalents may be listed where approved.
Active patent-based delay is unlikely.
Paragraph IV litigation risk is low.
A new generic entrant would more likely face regulatory and commercial execution risks than patent litigation.

The absence of an active patent barrier does not guarantee rapid market share capture. Injectable products can remain concentrated because dental distributors favor suppliers with dependable inventory and established quality records.

Are there Paragraph IV challenges or patent litigation?

Paragraph IV litigation risk is low. Paragraph IV certifications challenge patents listed in the Orange Book as invalid, unenforceable or not infringed. A product with no meaningful active patent estate offers little basis for a commercially important Paragraph IV dispute.

No major ongoing patent litigation is expected to determine market access for the combination. The more relevant disputes would involve:

Product liability claims
Manufacturing defects
Sterility failures
Supply agreements
Trademark rights
Distribution contracts
Regulatory enforcement

For investors and licensors, the absence of patent litigation is not evidence of a strong moat. It indicates that the product competes primarily as a mature generic injectable.

What is the market size and revenue exposure?

Public companies generally do not report revenue separately for mepivacaine hydrochloride with levonordefrin. Sales are usually aggregated with dental anesthetics, local anesthetics, hospital injectables or broader pharmaceutical segments.

As a result, product-level revenue, gross margin and market-share estimates cannot be derived reliably from public company filings alone. The product’s financial profile can still be characterized:

Financial factor	Expected effect
Dental procedure volume	Primary demand driver
Generic competition	Sustained price pressure
Product differentiation	Limited
Unit price	Low relative to specialty drugs
Manufacturing complexity	Supports some supplier concentration
Distributor contracts	Can stabilize volume
Supply interruptions	Can create short-term price and share changes
Patent expiry	No future cliff; loss of exclusivity is historical
R&D requirement	Low
Commercial expenditure	Focused on supply, contracting and distribution

Dental demand is linked to the number of restorative, surgical and emergency procedures. U.S. dental utilization has recovered from pandemic-era disruption, but procedure growth is constrained by insurance coverage, affordability, staffing and patient access. The American Dental Association’s Health Policy Institute tracks dental visits, utilization and practice economics, which are relevant demand indicators for dental anesthetic suppliers (American Dental Association Health Policy Institute, n.d.).

What is the financial trajectory for this drug?

The likely financial trajectory is mature and volume-oriented:

Near term

Revenue should depend on dental procedure recovery, inventory availability and contract retention. Price increases may occur during shortages, but sustained pricing power is limited because multiple therapeutic alternatives exist.

Medium term

The market is likely to experience low nominal growth, with revenue affected by:

Generic price erosion
Consolidation among dental distributors
Dental service organization purchasing
Migration toward articaine or lidocaine products
Supplier exits
Changes in cartridge manufacturing capacity

Long term

The product is unlikely to generate pharmaceutical-style growth. Its value is closer to a dependable consumables franchise than to an innovation asset. A manufacturer can produce attractive returns if it operates at scale, maintains high utilization and avoids quality events. Returns deteriorate rapidly when production runs below capacity or when remediation costs follow a regulatory action.

The combination has no obvious catalyst for a sharp revenue increase. Potential upside would come from a supply disruption affecting competitors, a distribution agreement, expansion into an underpenetrated geographic market or a broader increase in dental procedure volumes.

How strong is the patent estate compared with competing dental anesthetics?

The patent estate is weak across the mature local-anesthetic category.

Product category	Patent strength	Commercial protection
Mepivacaine with levonordefrin	Low	Manufacturing and distribution
Plain mepivacaine	Low	Manufacturing and distribution
Lidocaine with epinephrine	Low	Scale and formulary position
Articaine with epinephrine	Low to moderate by market	Brand history, formulation and distribution
Long-acting novel dental anesthetics	Potentially higher	Clinical differentiation and active patents, if applicable

Mepivacaine with levonordefrin is therefore weaker than newer or reformulated anesthetics that can support clinical differentiation. Its defensibility comes from execution rather than intellectual property.

What generic launch scenarios exist?

A new generic supplier could enter through three practical routes:

Obtain approval for a therapeutically equivalent injectable product and compete on price.
Acquire or license an existing approved product and improve supply reliability.
Enter through a regional or contract-manufacturing arrangement focused on dental distributors.

The fastest commercial launch would likely depend on an existing FDA-approved sterile facility and an established dental sales channel. A company starting without those assets would face a longer commercialization period despite the lack of patent barriers.

A successful entrant would probably target distributor contracts and supply reliability rather than physician-level promotion. The principal risk is that the market is too small to support multiple inefficient manufacturers at attractive margins.

What is the geographic coverage?

The United States is a distinct market because of FDA approval, dental cartridge standards and Orange Book-based generic substitution. Other markets may use different concentrations, vasoconstrictors, packaging formats and brand names.

Levonordefrin is less internationally prominent than epinephrine-containing dental anesthetics. Geographic expansion therefore requires local registration, pharmacovigilance, packaging compliance and distributor relationships. It should not be assumed that U.S. approval automatically supports international commercialization.

Key Takeaways

Mepivacaine hydrochloride with levonordefrin is a mature dental local anesthetic combination.
Its core patent protection has expired, and current patent-based exclusivity is not commercially meaningful.
Generic competition is established, with low Paragraph IV and patent-litigation risk.
Sterile cartridge manufacturing, FDA compliance and distribution are the main entry barriers.
The product competes with plain mepivacaine, lidocaine with epinephrine and articaine with epinephrine.
Product-level revenue is generally not disclosed by manufacturers.
Financial performance is driven by dental procedure volumes, supply reliability, contract pricing and manufacturing utilization.
The asset has limited innovation upside and is better evaluated as a mature, supply-sensitive generic franchise.
Biosimilar risk does not apply because the product is a small-molecule drug.
Any investment case depends on manufacturing scale, channel access and the probability of competitor supply disruption rather than on patent life.

FAQs

Is mepivacaine with levonordefrin still under patent?

No commercially meaningful core patent protection is expected to remain. The active ingredients and established dental formulation are mature.

Is mepivacaine with levonordefrin interchangeable with lidocaine with epinephrine?

They are therapeutic alternatives, but they are not identical products. Selection depends on clinical indication, patient factors, duration requirements, vasoconstrictor preference and local labeling.

Does this drug have biosimilar competition?

No. Biosimilar regulation applies to biologic products. Mepivacaine with levonordefrin is a small-molecule injectable drug and competes through generic approval pathways.

What would cause a shortage of mepivacaine with levonordefrin?

Likely causes include sterile manufacturing deviations, cartridge-component shortages, limited filling capacity, quality investigations, regulatory action and distributor inventory disruptions.

Is mepivacaine with levonordefrin an attractive licensing asset?

It may be attractive for a manufacturer with underused sterile capacity and established dental distribution. It is less attractive as a standalone intellectual-property asset because patent exclusivity and clinical differentiation are limited.

References

American Dental Association Health Policy Institute. (n.d.). Dental care utilization and oral health policy data. https://www.ada.org/resources/research/health-policy-institute
U.S. Food and Drug Administration. (n.d.-a). Mepivacaine hydrochloride and levonordefrin injection prescribing information. DailyMed. https://dailymed.nlm.nih.gov/
U.S. Food and Drug Administration. (n.d.-b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

US Patents:	0
Applicants:	1
NDAs:	1
Clinical Trials:	4
DailyMed Link:	MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN at DailyMed

MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN Drug Patent Profile

When do Mepivacaine Hydrochloride W/ Levonordefrin patents expire, and when can generic versions of Mepivacaine Hydrochloride W/ Levonordefrin launch?

AI Deep Research

Questions you can ask:

Summary for MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

Recent Clinical Trials for MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

US Patents and Regulatory Information for MEPIVACAINE HYDROCHLORIDE W/ LEVONORDEFRIN

Mepivacaine Hydrochloride With Levonordefrin: Market Dynamics, Patent Status and Financial Trajectory